A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
NCT04892017 · TERMINATED · Phase 1
We track 1 ClinicalTrials.gov studies led by Deciphera Pharmaceuticals Llc. The portfolio skews toward Phase 1 (1 trials).
1 clinical trials sponsored by Deciphera Pharmaceuticals Llc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 1 | 100% |
Deciphera Pharmaceuticals Llc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 1.
Deciphera Pharmaceuticals Llc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.